Showing results (101-110 of 181) with videos related to

Sort By:
Pageof 19
Mutation Research|December 1, 1992
Urban air pollution: use of different mutagenicity assays to evaluate environmental genetic hazardP Poli, A Buschini, N Campanini, et al.
Toxicology Letters|May 1, 1995
Occupational genotoxicity assessment by mutagenicity assaysC Rossi, P Poli, A Buschini, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 18, 2003
Influence of age on the association between primary hemifacial spasm and arterial hypertensionG Defazio, D Martino, M S Aniello, et al.
The Science of the Total Environment|January 16, 2003
Evaluation of the migration of mutagens/carcinogens from PET bottles into mineral water by Tradescantia/micronuclei test, Comet assay on leukocytes and GC/MSD Biscardi, S Monarca, R De Fusco, et al.
Cancer Chemotherapy and Pharmacology|July 21, 1999
Protracted continuous infusion of 5-fluorouracil and low-dose leucovorin in patients with metastatic colorectal cancer resistant to 5-fluorouracil bolus-based chemotherapy: a phase II studyA Falcone, G Allegrini, M Lencioni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly scheduleG Masi, G Allegrini, S Cupini, et al.
The Bone & Joint Journal|February 1, 2019
Trifocal versus bifocal bone transport in treatment of long segmental tibial bone defectsM A Catagni, W Azzam, F Guerreschi, et al.
Oncology|July 28, 2001
5-fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a randomized phase II study in metastatic colorectal cancerA Falcone, G Allegrini, G Masi, et al.
Infection|January 31, 2016
Listeria meningoencephalitis and anti-GQ1b antibody syndromeA Vergori, G Masi, D Donati, et al.
Cancer|August 3, 1999
Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinomaA Falcone, A Antonuzzo, R Danesi, et al.
Pageof 19